stanford school of medicine logotitle logo
advanced

 

 

Cardiology

 

Endocrinology

 

Gastroenterology

 

General Inpatient Medicine

 

Hematology

 

Infectious Disease

 

Nephrology

 

Neurology

 

Oncology

 

Outpatient & Preventative Medicine

 

Palliative Care

 

Psychiatry

 

Pulmonary/Critical Care

 

Rheumatology

Candidura, Candidemia and Candidal Endocarditis

1) Review Candiduria and Indications for treatment

  • Candiduria is extremely common and usually represents colonization, not true infection.
  • Main risk factor is presence of foley
  • Do not treat asymptomatic candiduria, unless 1) Neutropenic, or 2) Undergoing urological procedure (e.g. TURP).
  • However, if isolate candida from multiple sites (i.e. sputum and urine), in the appropriate clinical setting can be worrisome for disseminated candidiasis.
  • For symptomatic candiduria, best treatment is to remove foley.  If that doesn't work, Fluconazole is drug of choice.  Ampho B bladder washes are NOT recommended (high relapse rate, and associated with higher mortality vs fluconazole).  Echinocandins do not reliably penetrate the urine.

 

2) Candidemia: Significance of blood cultures, Clinical Presentation and Workup, and Risk Factors

  • Blood cultures are insensitive for candidemia (as opposed to bacteremia - more sensitive).  Classically, ~50% sensitive (but newer blood culture systems likely better than that).
  • NEVER DISREGARD CANDIDA IN THE BLOOD AS A CONTAMINANT.  Believe it or not, a few times a year this happens.  ALWAYS TREAT CANDIDEMIA AND WORK IT UP: i.e., find out why he is candidemic, look for complications (i.e. endophthalmitis, possibly endocarditis)
  • Clinical presentation can range from asymptomatic to septic shock - again, even if pt looks well, never disregard candida in the blood as contaminant!!
  • All pts with candidemia automatically warrant an ophtho consult for a dilated retinal exam to r/o endophthalmitis, which occurs in ~10-25% of cases.  Significance of this is that if severe eye lesions are present, this warrants combination therapy (i.e. Amphoterecin + Flucytosine) and much longer course of therapy (> 6 weeks minimum).
  • Always dc and replace central lines in patients with candidemia

Risk Factors for Invasive Candidiasis - note that candida is part of the endogenous bowel flora, and also transmitted nosocomially on hands of health-care workers.

  • Central lines - Candida is the 4th most common cause of CVC infections
  • Broad spectrum antibiotics
  • TPN - fungi love the nutritious medium (esp C.parapsilosis)
  • Neutropenia, immunocompromised (often due to gut translocation)
  • IV drug abuse
  • Bowel surgery esp with anastomotic leaks

 

3) Review Antifungal Agents for Candidiasis.

  • Fluconazole - can be used for C.albicans, C.parapsilosis, and C. tropicalis.  C.glabrata and C.krusei are resistant and increasingly common.  Excellent PO bioavailability.
  • Echinocandins (Caspofungin, Micafungin, Anidulafungin) - work against virtually all strains, except potentially C.parapsilosis (higher MICs in vitro, but still usually responds clinically) --> drugs of choice for most pts (esp unstable pts) with candidemia
  • Amphoterecin B - works against most (not all) strains of Candida, but little advantage over echinocandins and much more toxic

 

4) Management of Candidal Endocarditis:

  • Medical: Per 2009 IDSA guidelines, warrants combination therapy with Amphoterecin B + Flucytosine, or Amphoterecin B + Echinocandin. 
  • Surgical: Strong indication for valve replacement therapy, as very difficult to eradicate with antifungals alone.

** Other indications for surgery in endocarditis:
Class I: - New onset heart failure due to valvular dysfunction, or hemodynamic deterioration
            - Invasive complications: Perivalvular abscess, conduction abnormalities
            - Fungal endocarditis, or other highly resistant organisms
Class II:- Large (> 10 mm) vegetations
            - Recurrent systemic emboli while on appropriate antimicrobial therapy.

 

 

(Chanu Rhee MD, 7/23/10)